WO2004009543A3 - 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors - Google Patents

1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors Download PDF

Info

Publication number
WO2004009543A3
WO2004009543A3 PCT/EP2003/008138 EP0308138W WO2004009543A3 WO 2004009543 A3 WO2004009543 A3 WO 2004009543A3 EP 0308138 W EP0308138 W EP 0308138W WO 2004009543 A3 WO2004009543 A3 WO 2004009543A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolidine
hepatitis
cyano
carbonyl
carboxylic acid
Prior art date
Application number
PCT/EP2003/008138
Other languages
French (fr)
Other versions
WO2004009543A8 (en
WO2004009543A2 (en
Inventor
George Burton
Helen Susanne Goodland
David Haigh
Terence John Kiesow
Thomas W Ku
Martin John Slater
Original Assignee
Glaxo Group Ltd
George Burton
Helen Susanne Goodland
David Haigh
Terence John Kiesow
Thomas W Ku
Martin John Slater
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, George Burton, Helen Susanne Goodland, David Haigh, Terence John Kiesow, Thomas W Ku, Martin John Slater filed Critical Glaxo Group Ltd
Priority to AU2003266243A priority Critical patent/AU2003266243A1/en
Publication of WO2004009543A2 publication Critical patent/WO2004009543A2/en
Publication of WO2004009543A3 publication Critical patent/WO2004009543A3/en
Publication of WO2004009543A8 publication Critical patent/WO2004009543A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel anti-viral agents of Formula (I) wherein: A represents OH; B represents C(O)R1 wherein R1 is selected from the group consisting of C1-6alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents hydrogen or C1-6alkyl; E represents hydrogen, C1-6alkyl, aryl or heteroaryl; and F represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.
PCT/EP2003/008138 2002-07-22 2003-07-18 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors WO2004009543A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003266243A AU2003266243A1 (en) 2002-07-22 2003-07-18 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0216985A GB0216985D0 (en) 2002-07-22 2002-07-22 Compounds
GB0216985.2 2002-07-22

Publications (3)

Publication Number Publication Date
WO2004009543A2 WO2004009543A2 (en) 2004-01-29
WO2004009543A3 true WO2004009543A3 (en) 2004-03-18
WO2004009543A8 WO2004009543A8 (en) 2004-06-10

Family

ID=9940904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008138 WO2004009543A2 (en) 2002-07-22 2003-07-18 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors

Country Status (3)

Country Link
AU (1) AU2003266243A1 (en)
GB (1) GB0216985D0 (en)
WO (1) WO2004009543A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
CA2585383A1 (en) * 2004-10-29 2006-05-11 Gerald W. Shipps, Jr. Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
ATE548044T1 (en) 2007-05-04 2012-03-15 Vertex Pharma COMBINATION THERAPY FOR THE TREATMENT OF HIV INFECTIONS
WO2012031763A1 (en) * 2010-09-08 2012-03-15 Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085720A1 (en) * 2000-05-05 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
WO2003037893A1 (en) * 2001-11-02 2003-05-08 Glaxo Group Limited Acyl dihydro pyrrole derivatives as hcv inhibitors
WO2003037894A1 (en) * 2001-11-02 2003-05-08 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085720A1 (en) * 2000-05-05 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
WO2003037893A1 (en) * 2001-11-02 2003-05-08 Glaxo Group Limited Acyl dihydro pyrrole derivatives as hcv inhibitors
WO2003037894A1 (en) * 2001-11-02 2003-05-08 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors

Also Published As

Publication number Publication date
AU2003266243A1 (en) 2004-02-09
AU2003266243A8 (en) 2004-02-09
WO2004009543A8 (en) 2004-06-10
WO2004009543A2 (en) 2004-01-29
GB0216985D0 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
NO20052472L (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections.
WO2005090383A3 (en) Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections
WO2006027628A3 (en) Naphthalimide derivatives as antiviral agents
WO2002064547A3 (en) Isophthalic acid derivatives as matrix metalloproteinase inhibitors
EP2546246A3 (en) Compounds and methods for the treatment or prevention of flavivirus infections
RS67204A (en) Tripeptides having a hydroxyproline ether of a substituted quinoline for inhibition of ns3 (hepatitis c)
UA83046C2 (en) Hepatitis c inhibitor compounds, pharmaceutical composition based thereon
WO2008021927A3 (en) Hepatitis c virus inhibitors
WO2007084413A3 (en) Methods for treating hepatitis c
WO2005054430A3 (en) Hepatitis c virus inhibitors
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004032827A3 (en) Hepatitis c virus inhibitors
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2005061501A3 (en) Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds
WO2003064455A3 (en) Macrocyclic peptides active against the hepatitis c virus
MXPA05006196A (en) Compounds and methods for the treatment or prevention of flavivirus.
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
WO2006113552A8 (en) Cyanoarylamines
ATE332304T1 (en) CEFDINIR SALTS AS INTERMEDIATE PRODUCTS
EP1688420A4 (en) 5-5-membered fused heterocyclic compound and use thereof as hcv polymerase inhibitor
NO983435L (en) Disclosed are
WO2007080270A3 (en) New cholest-4-en-3-one oxime derivatives, pharmaceutical compositions comprising them, and preparation process
EA200600046A1 (en) DERIVATIVES 6- [2- (PHOSPHONOMOTOXY) ALKOXI] Pyrimidine (OPTIONS), METHOD OF THEIR RECEIVING (OPTIONS), PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND METHOD OF TREATING VIRAL INFECTION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION; PUBLISHED FIGURE REPLACED BY CORRECT FIGURE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP